Pacira BioSciences (STU:82P) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:82P Pacira BioSciences Inc STU:82P
75 GF Score
Price €22.80
GF Value €25.82
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:82P vs ALVO, BIOA, COLL: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacira BioSciences Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Short Interest falls into.


STU:82P
75GF Score
Pacira BioSciences Inc STU:82P
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pacira BioSciences (STU:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.80 is trading 11.7% below its estimated GF Value™ of €25.82. GuruFocus considers Pacira BioSciences to be Modestly Undervalued.

Key valuation signals for STU:82P:

  • Short Interest:
  • GF Value™: €25.82 vs. price of €22.80 (11.7% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the STU:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score

Get the complete analysis for STU:82P

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.80
Price
€25.82
GF Value